10月8日，安进盘中下跌3.07%，报400.405美元/股，成交额1.07亿美元。
消息面上，摩根士丹利将安进目标价从362美元小幅调整至359美元，尽管Truist同日将目标价上调至380美元，但大摩的谨慎立场仍引发市场对前期涨幅的获利了结情绪。此前安进在9月下旬因Dazodalibep干燥综合征III期成功及Repatha心血管死亡风险降低20%等利好推动股价大幅上行，10月7日一度涨超3%，短线累积的获利盘在权重机构评级分歧下选择兑现离场。
安进公司于1980年在加利福尼亚成立，专注于高度未满足的医疗需求领域，已成长为世界领先的独立生物技术公司之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.